metformin has been researched along with Atypical Ductal Hyperplasia in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We present the results of a new analysis of our study on the effect of metformin on the bioavailability of sex hormones." | 6.78 | Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. ( Abbà, C; Berrino, F; Biglia, N; Brucato, T; Campagnoli, C; Cogliati, P; Danese, S; Donadio, M; Pasanisi, P; Venturelli, E; Zito, G, 2013) |
| "Metformin is associated with lower breast cancer risk in epidemiologic studies and showed decreased proliferation in HER2-positive breast cancer in a presurgical trial." | 5.20 | Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial. ( Bonanni, B; Cazzaniga, M; Cuzick, J; DeCensi, A; Gentilini, O; Guerrieri-Gonzaga, A; Lazzeroni, M; Petrera, M; Pruneri, G; Puntoni, M; Serrano, D; Viale, G; Vingiani, A, 2015) |
| " The goal of this study was to assess protein marker changes by RPPA in tumor tissue from a pre-surgical metformin trial in women with operable breast cancer (BC)." | 3.85 | Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial. ( Connolly, E; Crew, KD; Du, X; Feldman, SM; Hershman, DL; Hibshoosh, H; Kalinsky, K; Maurer, MA; Mundi, P; Refice, S; Taback, B; Yang, J; Zheng, T, 2017) |
| " We present the results of a new analysis of our study on the effect of metformin on the bioavailability of sex hormones." | 2.78 | Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. ( Abbà, C; Berrino, F; Biglia, N; Brucato, T; Campagnoli, C; Cogliati, P; Danese, S; Donadio, M; Pasanisi, P; Venturelli, E; Zito, G, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campagnoli, C | 1 |
| Berrino, F | 1 |
| Venturelli, E | 1 |
| Abbà, C | 1 |
| Biglia, N | 1 |
| Brucato, T | 1 |
| Cogliati, P | 1 |
| Danese, S | 1 |
| Donadio, M | 1 |
| Zito, G | 1 |
| Pasanisi, P | 1 |
| DeCensi, A | 1 |
| Puntoni, M | 1 |
| Guerrieri-Gonzaga, A | 1 |
| Cazzaniga, M | 1 |
| Serrano, D | 1 |
| Lazzeroni, M | 1 |
| Vingiani, A | 1 |
| Gentilini, O | 1 |
| Petrera, M | 1 |
| Viale, G | 1 |
| Cuzick, J | 1 |
| Bonanni, B | 1 |
| Pruneri, G | 1 |
| Kalinsky, K | 1 |
| Zheng, T | 1 |
| Hibshoosh, H | 1 |
| Du, X | 1 |
| Mundi, P | 1 |
| Yang, J | 1 |
| Refice, S | 1 |
| Feldman, SM | 1 |
| Taback, B | 1 |
| Connolly, E | 1 |
| Crew, KD | 1 |
| Maurer, MA | 1 |
| Hershman, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation[NCT00930579] | Phase 2 | 35 participants (Actual) | Interventional | 2009-10-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This outcome measure examines the changes in tumor proliferation as measured by the amount of Ki-67 protein in the tumor. (NCT00930579)
Timeframe: Baseline, up to 4 weeks
| Intervention | percentage of ki-67 positive cells (Mean) | |
|---|---|---|
| Premetformin Tumor Sample | Post Metformin Tumor Sample | |
| Metformin | 2.17 | 2.165 |
2 trials available for metformin and Atypical Ductal Hyperplasia
| Article | Year |
|---|---|
Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer.
Topics: Aged; Androgens; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Diabetes Mellitus; Estro | 2013 |
Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Proliferation; Double-B | 2015 |
1 other study available for metformin and Atypical Ductal Hyperplasia
| Article | Year |
|---|---|
Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Carcinoma, Intraductal, Noninfilt | 2017 |